THC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenet Healthcare Corp (THC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, hedge fund buying activity, and favorable options data support this decision. While the stock has seen a slight decline today, its long-term growth potential and recent analyst upgrades make it a solid investment opportunity.
The technical indicators are mixed but lean slightly bullish. The MACD is above 0 and positively contracting, suggesting mild bullish momentum. The RSI is neutral at 51.899, indicating no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot point of 237.664, with key support at 229.906 and resistance at 245.422.
Strong Q4 financial performance with revenue up 8.95% YoY, net income up 16.67% YoY, and EPS up 27.88% YoY.
Hedge fund buying activity has surged by 337.36% in the last quarter.
Analysts have consistently raised price targets, with the highest target at $288, significantly above the current price.
The healthcare sector showed strong job growth, which could benefit Tenet Healthcare.
Gross margin declined slightly by 0.40% YoY in Q
The stock is down 1.76% today, reflecting short-term market weakness.
Broader market sentiment is negative, with the S&P 500 down 0.85%.
In Q4 2025, Tenet Healthcare reported strong financial results. Revenue increased by 8.95% YoY to $5.53 billion, net income rose by 16.67% YoY to $371 million, and EPS grew by 27.88% YoY to 4.22. However, gross margin slightly declined by 0.40% YoY to 77.55%. Overall, the company demonstrated robust growth and profitability.
Analysts are overwhelmingly positive on Tenet Healthcare. Multiple firms, including Truist, Wells Fargo, Barclays, Guggenheim, and RBC Capital, have raised their price targets, with the highest target at $288. Analysts highlight strong fundamentals, better-than-expected Q4 results, and favorable 2026 guidance as key drivers for their optimism.
